Drug intelligence / Profile preview

BAU-243

Development stage: Preclinical
Lead developer: Bahçeşehir University
Modality: Small Molecules

Overview

BAU-243 is a novel small molecule BCL-2 inhibitor being developed for the treatment of glioblastoma (GBM). Identified through a multistep virtual screening of over 210,000 compounds, BAU-243 demonstrates high affinity for the B-cell leukemia/lymphoma-2 (BCL-2) protein. Unlike selective BCL-2 inhibitors such as venetoclax (ABT-199) which primarily induce apoptosis, BAU-243 induces autophagic cell death in GBM cells, including cancer-initiating cells, by disrupting the Beclin 1:Bcl-2 complex. In preclinical orthotopic brain tumor models, BAU-243 has shown a significant reduction in tumor growth compared to vehicle and venetoclax-treated groups.

Targets

BCL-2 (BCL-2 family)

Beyond the preview

Go deeper on BAU-243.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on BAU-243.

Explore the full profile